Hypogefractioneerde Versus Normofractionated Accelerated Radiotherapie With or Without Cisplatin for Locally Gevorderd Hoofd-hals Squamous Cell Carcinoma (HYPNO): Een gerandomiseerde, Open-Label, Phase 3, Noninferiority Trial

Based on bioeffect modeling of published outcomes after radiation therapy for head and neck squamous cell carcinoma with various time-dose-fractionation, we hypothesized that a 20-fraction hypofractionated (HFX) schedule delivering 55 Gy in 20 fractions, 5 fractions per week, over 4 weeks would be noninferior to a 33-fraction accelerated, normofractionated (NFX) 2 Gy per fraction schedule, delivering 66 Gy in 2-Gy fractions, 6 fractions per week over 5.5 weeks with respect to both local tumor control and late adverse events.